A Multicenter Clinical Trial: Efficacy, Safety of Fecal Microbiota Transplantation for Inflammatory Bowel Disease
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
There are many limitations in the current treatments of Inflammatory bowel disease(IBD). Some
patients have no or little reaction to the traditional drugs. Now the investigators realized
that the intestinal microbiota is closely associated with the development of IBD. In recent
years, a retrospective study showed that the overall efficiency of fecal microbiota
transplantation (FMT) for IBD was 79%, the overall remission rate was 43%, which opened a new
chapter in the treatment of IBD. So the standardized fecal microbiota transplantation is
considered to be simple but effective emerging therapies for the treatment of IBD. In this
project the investigators intend to carry out a single-center, randomized, single-blind
clinical intervention study. The investigators plan to recruit patients with IBD (Ulcerative
Colitis and Crohn's Disease) in China. The patients will be randomly divided into two groups,
one group will be given treatment of standardized fecal microbiota transplantation, the other
will be simply treated with traditional drugs, followed up for at least 1 year. The
investigators aim to determine the efficiency, durability and safety of Fecal Microbiota
Transplantation for IBD treatment, and further to explore which major microbiota may effect
in this project.